JP2016531871A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016531871A5 JP2016531871A5 JP2016517444A JP2016517444A JP2016531871A5 JP 2016531871 A5 JP2016531871 A5 JP 2016531871A5 JP 2016517444 A JP2016517444 A JP 2016517444A JP 2016517444 A JP2016517444 A JP 2016517444A JP 2016531871 A5 JP2016531871 A5 JP 2016531871A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- mucositis
- composition according
- haloalkyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 22
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims description 17
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 17
- 201000010927 Mucositis Diseases 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 125000000304 alkynyl group Chemical group 0.000 claims description 12
- 125000000262 haloalkenyl group Chemical group 0.000 claims description 12
- 125000000232 haloalkynyl group Chemical group 0.000 claims description 12
- 229940123546 E-selectin antagonist Drugs 0.000 claims description 10
- 229940002612 prodrug Drugs 0.000 claims description 7
- 239000000651 prodrug Substances 0.000 claims description 7
- 102000015689 E-Selectin Human genes 0.000 claims description 6
- 108010024212 E-Selectin Proteins 0.000 claims description 6
- 206010064147 Gastrointestinal inflammation Diseases 0.000 claims description 6
- 208000018925 gastrointestinal mucositis Diseases 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000002412 selectin antagonist Substances 0.000 claims description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010030216 Oesophagitis Diseases 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 208000003265 stomatitis Diseases 0.000 claims description 4
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 229940124761 MMP inhibitor Drugs 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 230000000845 anti-microbial effect Effects 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 210000003630 histaminocyte Anatomy 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 125000005647 linker group Chemical group 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 39
- 229940079593 drug Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 33
- OJXGCWQFAGRXFL-AGEIFGMDSA-N CCC(CC(C[C@H]1OC(C(NC(C)=O)OC(CC2CCCCC2)C(O)=O)OC(CO)[C@@H](C)O)C(NCCNC(C(C)(CC)CCOC(C)(C)C)=O)=O)C1OC([C@H](C1O)O)O[C@@H](C)C1O Chemical compound CCC(CC(C[C@H]1OC(C(NC(C)=O)OC(CC2CCCCC2)C(O)=O)OC(CO)[C@@H](C)O)C(NCCNC(C(C)(CC)CCOC(C)(C)C)=O)=O)C1OC([C@H](C1O)O)O[C@@H](C)C1O OJXGCWQFAGRXFL-AGEIFGMDSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361884856P | 2013-09-30 | 2013-09-30 | |
| US61/884,856 | 2013-09-30 | ||
| PCT/US2014/057978 WO2015048616A1 (en) | 2013-09-30 | 2014-09-29 | Methods and compositions for treating and/or preventing mucositis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016531871A JP2016531871A (ja) | 2016-10-13 |
| JP2016531871A5 true JP2016531871A5 (enExample) | 2017-10-05 |
Family
ID=52744558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016517444A Pending JP2016531871A (ja) | 2013-09-30 | 2014-09-29 | 粘膜炎を治療および／または予防するための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20170296566A9 (enExample) |
| EP (1) | EP3052510A4 (enExample) |
| JP (1) | JP2016531871A (enExample) |
| CN (1) | CN105683208A (enExample) |
| AU (1) | AU2014324634A1 (enExample) |
| CA (1) | CA2925119A1 (enExample) |
| WO (1) | WO2015048616A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE038423T2 (hu) | 2012-12-07 | 2018-10-29 | Glycomimetics Inc | E-szelektin antagonistákat felhasználó vegyületek, készítmények és eljárások vérképzõ sejtek mobilizációjára |
| CN107108679B (zh) | 2014-12-03 | 2020-10-23 | 糖模拟物有限公司 | E-选择蛋白和cxcr4趋化因子受体的异双官能抑制剂 |
| CA3002883A1 (en) * | 2015-11-03 | 2017-05-11 | Glycomimetics, Inc. | Antibodies for targeting cancer stem cells and treating aggressive cancers |
| US11291678B2 (en) | 2016-03-02 | 2022-04-05 | Glycomimetics, Inc | Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin |
| US20200316100A1 (en) * | 2016-05-24 | 2020-10-08 | GycoMimetics, Inc. | Haloalkyl fucose-containing selectin antagonists |
| US11433086B2 (en) | 2016-08-08 | 2022-09-06 | Glycomimetics, Inc. | Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4 |
| BR112019006642A2 (pt) | 2016-10-07 | 2019-07-02 | Glycomimetics Inc | antagonistas multiméricos de e-selectina altamente potentes |
| CA3054605A1 (en) | 2017-03-15 | 2018-09-20 | Glycomimetics, Inc. | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists |
| EP3717013A1 (en) | 2017-11-30 | 2020-10-07 | GlycoMimetics, Inc. | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
| US11548908B2 (en) | 2017-12-29 | 2023-01-10 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
| AU2019230013A1 (en) | 2018-03-05 | 2020-09-10 | Glycomimetics, Inc. | Methods for treating acute myeloid leukemia and related conditions |
| WO2020123435A2 (en) * | 2018-12-10 | 2020-06-18 | Glycomimetics, Inc. | Methods of treating hiv and aids and the elimination of latent reservoirs of hiv infection using selectin, galectin, and siglec antagonists |
| US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
| MX2022002102A (es) * | 2019-08-20 | 2022-07-04 | Glycomimetics Inc | Proceso para preparar un intermediario inhibidor de e-selectina. |
| JP2023529485A (ja) * | 2020-06-14 | 2023-07-10 | グリコミメティクス， インコーポレイテッド | Ｅ－セレクチン標的化を介して微小環境媒介耐性を克服するための組成物および方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6458777B1 (en) * | 1998-03-13 | 2002-10-01 | Mucosal Therapeutics Llc | Methods and compositions for treating and preventing mucositis |
| SI2264043T1 (en) * | 2005-09-02 | 2018-01-31 | Glycomimetics, Inc. | HETEROBIFUNCTIONAL PAN-SELECTINE INHIBITORS |
| EP2794626B3 (en) * | 2011-12-22 | 2020-08-05 | GlycoMimetics, Inc. | E-selectin antagonist compounds |
| US20160333043A1 (en) * | 2014-01-17 | 2016-11-17 | Glycomimetics, Inc. | E-Selectin Antagonists Modified By Macrocycle Formation to the Galactose |
-
2014
- 2014-09-29 WO PCT/US2014/057978 patent/WO2015048616A1/en not_active Ceased
- 2014-09-29 AU AU2014324634A patent/AU2014324634A1/en not_active Abandoned
- 2014-09-29 US US15/025,730 patent/US20170296566A9/en not_active Abandoned
- 2014-09-29 CA CA2925119A patent/CA2925119A1/en not_active Abandoned
- 2014-09-29 JP JP2016517444A patent/JP2016531871A/ja active Pending
- 2014-09-29 CN CN201480057818.5A patent/CN105683208A/zh active Pending
- 2014-09-29 EP EP14849941.1A patent/EP3052510A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018530549A5 (enExample) | ||
| JP2019529518A5 (enExample) | ||
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| JP2016515561A5 (enExample) | ||
| JP2015078230A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| JP2016506916A5 (enExample) | ||
| JP2017511360A5 (enExample) | ||
| JP2016534148A5 (enExample) | ||
| JP2011523412A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| JP2015516427A5 (enExample) | ||
| RU2015149527A (ru) | Производные доластатина 10 и ауристатинов | |
| JP2015522650A5 (enExample) | ||
| JP2018517686A5 (enExample) | ||
| JP2017517565A5 (enExample) | ||
| JP2017141277A5 (enExample) | ||
| JP2017503833A5 (enExample) | ||
| JP2015521195A5 (enExample) | ||
| JP2018521056A5 (enExample) | ||
| JP2016515550A5 (enExample) | ||
| JP2019513829A5 (enExample) | ||
| RU2017141536A (ru) | Замещенные производные индол-5-ола и их терапевтические применения | |
| EA201692298A1 (ru) | Производные карбоксамидов |